Autres langues Arcus Biosciences, Inc.

Actions

RCUS

US03969F1093

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:03 11/08/2026			Varia. 5j.	Varia. 1 janv.
28,74 ^USD	+0,07%		-0,21%	+20,60%

10/08	Le traitement Casdatifan d'Arcus Biosciences pourrait être lancé en 2028, selon Morgan Stanley	MT
10/08	Arcus Biosciences, Inc. : Morgan Stanley conserve son opinion neutre	ZM

Autres langues

11/08	Arcus Biosciences Announces New Employment Inducement Grants
10/08	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
05/08	Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M
05/08	Arcus Biosciences : Reports Second-Quarter 2026 Financial Results and Provides a P...
05/08	Arcus Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
05/08	Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2026
27/07	Arcus Biosciences Announces New Employment Inducement Grants
22/07	Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
21/07	Arcus Biosciences : to Host Conference Call to Discuss Second-Quarter 2026 Financi...
21/07	Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
13/07	Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing
09/07	Arcus Biosciences Announces New Employment Inducement Grants
01/07	New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
24/06	Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing
24/06	Arcus Biosciences Announces New Employment Inducement Grants
09/06	Arcus Biosciences Announces New Employment Inducement Grants
04/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer
03/06	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
03/06	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial
03/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
03/06	Arcus Biosciences, Inc. and Bristol Myers Squibb Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer